US Blood Plasma Derivatives Market

ID: MRFR/Pharma/16771-HCR
100 Pages
Vikita Thakur
Last Updated: April 06, 2026
US Blood Plasma Derivatives Market Research Report By Type (Albumin, Immunoglobulin, Factor VIII, Factor IX, Hyperimmune Globulin),End-User (Medical Centers, Clinics), By Application (Hemophilia, Immunodeficiency Diseases, Hypogammaglobulinemia, Von Willebrand's Disease), By Region - Growth & Industry Forecast 2025 To 2035
US Blood Plasma Derivatives Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.86%
2024 Market Size$ 9.09 Billion
2025 Market Size$ 9.79 Billion
2035 Market Size$ 17.02 Billion
Key Players
Grifols
CSL Behring
Takeda Pharmaceutical Company Limited
Octapharma
Kedrion Biopharma
Bio Products Laboratory
Trends
  • Rising Demand for Immunoglobulins
  • Technological Advancements in Plasma Collection
  • Regulatory Developments and Compliance
Opportunities
  • Increasing Prevalence of Chronic Diseases
  • Rising Demand for Specialty Plasma Products
  • Regulatory Support for Plasma-Derived Therapies
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Life Sciences, BY Type (USD Billion)
      1. 4.1.1 Albumin
      2. 4.1.2 Immunoglobulin
      3. 4.1.3 Factor VIII
      4. 4.1.4 Factor IX
      5. 4.1.5 Hyperimmune Globulin
    2. 4.2 Life Sciences, BY Application (USD Billion)
      1. 4.2.1 Hemophilia
      2. 4.2.2 Immunodeficiency Diseases
      3. 4.2.3 Hypogammaglobulinemia
      4. 4.2.4 Von Willebrand's Disease
    3. 4.3 Life Sciences, BY End-User (USD Billion)
      1. 4.3.1 Medical Centers
      2. 4.3.2 Clinics
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Life Sciences
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Grifols (ES)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 CSL Behring (AU)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Takeda Pharmaceutical Company (JP)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Octapharma (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Kedrion (IT)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Biotest AG (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 LFB Group (FR)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Hualan Biological Engineering (CN)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 US MARKET ANALYSIS BY TYPE
    3. 6.3 US MARKET ANALYSIS BY APPLICATION
    4. 6.4 US MARKET ANALYSIS BY END-USER
    5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
    8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
    10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
    11. 6.11 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
    12. 6.12 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
    13. 6.13 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Billion)
    15. 6.15 LIFE SCIENCES, BY END-USER, 2024 (% SHARE)
    16. 6.16 LIFE SCIENCES, BY END-USER, 2024 TO 2035 (USD Billion)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY END-USER, 2025-2035 (USD Billion)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

US Blood Plasma Derivatives Market Segmentation

US Blood Plasma Derivatives Market By Type (USD Billion, 2025-2035)

  • Albumin
  • Immunoglobulin
  • Factor VIII
  • Factor IX
  • Hyperimmune Globulin

US Blood Plasma Derivatives Market By Application (USD Billion, 2025-2035)

  • Hemophilia
  • Immunodeficiency Diseases
  • Hypogammaglobulinemia
  • Von Willebrand's Disease

US Blood Plasma Derivatives Market By End-User (USD Billion, 2025-2035)

  • Medical Centers
  • Clinics

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.